Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Operating Leases (2019 - 2025)

Moleculin Biotech's Operating Leases history spans 7 years, with the latest figure at $222000.0 for Q4 2025.

  • Quarterly results put Operating Leases at $222000.0 for Q4 2025, down 37.99% from a year ago — trailing twelve months through Dec 2025 was $222000.0 (down 37.99% YoY), and the annual figure for FY2025 was $222000.0, down 37.99%.
  • Operating Leases for Q4 2025 was $222000.0 at Moleculin Biotech, down from $258000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $496000.0 in Q3 2023 to a low of $50000.0 in Q1 2022.
  • The 5-year median for Operating Leases is $317000.0 (2023), against an average of $295200.0.
  • The sharpest move saw Operating Leases crashed 79.92% in 2022, then soared 516.0% in 2023.
  • Year by year, Operating Leases stood at $63000.0 in 2021, then soared by 431.75% to $335000.0 in 2022, then surged by 41.49% to $474000.0 in 2023, then decreased by 24.47% to $358000.0 in 2024, then tumbled by 37.99% to $222000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $222000.0, $258000.0, and $292000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.